Pharmacokinetics of 11-nor-9-carboxy-Δ9- tetrahydrocannabinol (CTHC) after intravenous administration of CTHC in healthy human subjects

Clinical Pharmacology and Therapeutics

Volumn 82, Issue 1, 2007, Pages 63-69

  Glaz Sandberg, A ^a   Dietz, L ^a   Nguyen, H ^b   Oberwittler, H ^a   Aderjan, Rolf ^a   Mikus, Gerd ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

TETRAHYDROCANNABINOLIC ACID;

ADULT; ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; NAUSEA; NIGHT SWEAT; NORMAL HUMAN; PRIORITY JOURNAL;

ADULT; HALF-LIFE; HALLUCINOGENS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, BIOLOGICAL; REFERENCE VALUES; TETRAHYDROCANNABINOL;

EID: 34250677994     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100199     Document Type: Article

References (37)

1. Burstein, S. & Kupfer, D. Hydroxylation of trans-1- tetrahydrocannabinol by a hepatic microsomal monooxygenase. Chem. Biol. Interact. 3, 316 (1971).
2. Law, B., Mason, P.A., Moffat, A.C., Gleadle, R.I. & King, L.J Forensic aspects of the metabolism and excretion of cannabinoids following oral ingestion of cannabis resin. J. Pharm. Pharmacol. 36, 289-294 (1984).
3. Siemens, A.J. & Kalant, H. Metabolism of delta-1-tetrahydrocannabinol by the rat in vivo and in vitro. Biochem. Pharmacol. 24, 755-762 (1975).
4. Watanabe, K., Narimatsu, S., Yamamoto, I. & Yoshimura, H. Oxygenation mechanism in conversion of aldehyde to carboxylic acid catalyzed by a cytochrome P-450 isozyme. J. Biol. Chem. 266, 2709-2711 (1991).
5. Williams, P.L. & Moffat, A.C. Identification in human urine of delta 9-tetrahydrocannabinol-11-oic acid glucuronide: a tetrahydrocannabinol metabolite. J. Pharm. Pharmacol. 32, 445-448 (1980).
6. Pallante, S., Lyle, M.A. & Fenselau, C. Synthesis and characterization of glucuronides of 5′-hydroxy-delta9-tetrahydrocannabinol and 11-hydroxy-delta9-tetrahydrocannabinol. Drug Metab. Dispos. 6, 389-395 (1978).
7. Wall, M.E., Sadler, B.M., Brine, D., Taylor, H. & Perez-Reyes, M. Metabolism, disposition and kinetics of delta-9-tetrahydrocannabinol in men and women. Clin. Pharmacol. Ther. 34, 352-363 (1983).
8. Wall, M.E. & Perez-Reyes, M. The metabolism of delta 9 tetrahydrocannabinol and related cannabinoids in man. J. Clin. Pharmacol. 21, 178-189 (1981).
9. Halldin, M.M., Isaac, H., Widman, M., Nilsson, E. & Ryrfeldt, A. A comparison between the metabolism of delta 1-tetrahydrocannabinol by perfused lung and liver of rat and guinea pig. Xenobiotica 14, 277-282 (1984).
10. Huestis, M.A. & Cone, E.J. Urinary excretion half-life of 11-nor-9-carboxy-[DELTA]9-tetrahydrocannabinol in humans. Ther. Drug Monit. 20, 570-576 (1998).
11. Lemberger, L., Crabtree, R.E. & Rowe, H.M. 11-hydroxy-9- tetrahydrocannabinol: pharmacology, disposition, and metabolism of a major metabolite of marihuana in man. Science 177, 62-64 (1972).
12. Hunt, C.A. & Jones, R.T. Tolerance and disposition of tetrahydrocannabinol in man. J. Pharmacol. Exp. Ther. 215, 35-44 (1980).
13. Kelly, P. & Jones, R.T. Metabolism of tetrahydrocannabinol in frequent and infrequent marjuana users. J. Anal. Toxicol. 16, 228-235 (1992).
14. Huestis, M.A., Henningfield, J.E. & Cone, E.J. Blood cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana. J. Anal. Toxicol. 16, 276-282 (1992).
15. Johansson, E.K., Hollister, L.E. & Halldin, M.M. Urinary elimination half-life of delta-1-tetrahydrocannabinol-7-oic acid in heavy marijuana users after smoking. NIDA Res. Monogr. 95, 457-458 (1989).
16. Johansson, E. & Halldin, M.M. Urinary excretion half-life of delta 1-tetrahydrocannabinol-7-oic acid in heavy marijuana users after smoking. J. Anal. Toxicol. 13, 218-223 (1989).
17. Huestis, M.A., Mitchell, J.M. & Cone, E.J. Urinary excretion profiles of 11-nor-9-carboxy-delta 9-tetrahydrocannabinol in humans after single smoked doses of marijuana. J. Anal. Toxicol. 20, 441-452 (1996).
18. Kreuz, D.S. & Axelrod, J. Delta-9-tetrahydrocannabinol: localization in body fat. Science 179, 391-393 (1973).
19. Brunet, B. et al. Validation of large white pig as an animal model for the study of cannabinoids metabolism: application to the study of THC distribution in tissues. Forensic Sci. Int. 161, 169-174 (2006).
20. Johansson, E., Noren, K., Sjovall, J. & Halldin, M.M. Determination of delta 1-tetrahydrocannabinol in human fat biopsies from marihuana users by gas chromatography-mass spectrometry. Biomed. Chromatogr. 3, 35-38 (1989).
21. Johansson, E., Halldin, M., Agurell, S., Hollister, L.E. & Gillespie, H.K. Terminal elimination plasma half-life of delta 1-tetrahydrocannabinol (delta 1-THC) in heavy users of marijuana. Eur. J. Clin. Pharmacol. 37, 273-277 (1989).
22. Halldin, M.M., Carlsson, S., Kanter, S.L., Widman, M. & Agurell, S. Urinary metabolites of delta 1-tetrahydrocannabinol in man. Drug Res. 32, 764-768 (1982).
23. Halldin, M.M., Andersson, L.K., Widman, M. & Hollister, L.E. Further urinary metabolites of delta 1-tetrahydrocannabinol in man. Drug Res. 32, 1135-1138 (1982).
24. Nadulski, T. et al. Simultaneous and sensitive analysis of THC, 11-OH-THC, THC-COOH, CBD, and CBN by GC-MS in plasma after oral application of small doses of THC and cannabis extract. J. Anal. Toxicol. 29, 782-789 (2005).
25. Nadulski, T. et al. Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Delta9-tetrahydrocannabinol (THC) after oral application of THC versus standardized cannabis extract. Ther. Drug Monit. 27, 799-810 (2005).
26. Brenneisen, R., Egli, A., Elsohly, M.A., Henn, V. & Spiess, Y. The effect of orally and rectally administered delta 9-tetrahydrocannabinol on spasticity: a pilot study with 2 patients. Int. J Clin. Pharmacol. Ther. 34, 446-452 (1996).
27. Frytak, S., Moertel, C.G. & Rubin, J. Metabolic studies of delta-9-tetrahydrocannabinol in cancer patients. Cancer Treat. Rep. 68, 1427-1431 (1984).
28. Goodwin, R.S., Gustafson, R.A., Barnes, A., Nebro, W., Moolchan, E.T. & Huestis, M.A. Delta(9)-tetrahydrocannabinol, 11-hydroxy-delta(9)- tetrahydrocannabinol and 11-nor-9-carboxy-delta(9)-tetrahydrocannabinol in human plasma after controlled oral administration of cannabinoids. Ther. Drug Monit. 28, 545-551 (2006).
29. Gustafson, R.A. et al. Urinary pharmacokinetics of 11-nor-9-carboxy-delta9-tetrahydrocannabinol after controlled oral delta9-tetrahydrocannabinol administration. J. Anal. Toxicol. 28, 160-167 (2004).
30. Moeller, M.R., Doerr, G. & Warth, S. Simultaneous quantitation of delta-9-tetrahydrocannabinol (THC) and 11-nor-9-carboxydelta-9- tetrahydrocannabinol (THC-COOH) in serum by GC/MS using deuterated internal standards and its application to a smoking study and forensic cases. J. Forensic Sci. 37, 969-983 (1992).
31. Daldrup, T., Käferstein, H., Köhler, H., Maier, R.D. & Musshoff, F. Entscheidung zwischen einmaligem/gelegentlichem und regelmässigem Cannabiskonsum/ Deciding between one off/occasional and regular cannabis consumption. Blutalkohol 37, 39-47 (2000).
32. Huestis, M.A., Henningfield, J.E. & Cone, E.J. Blood concentrations. II. Models for the prediction of time of marijuana exposure from plasma concentrations of delta-9-tetrahydrocannabinol (THC) and 11-nor-9-carboxy-delta- 9-tetrahydrocannabinol (THCCOOH). J. Anal. Toxicol. 16, 283-289 (1992).
33. Huestis, M.A., Barnes, A. & Smith, M.L. Estimating the time of last cannabis use from plasma Delta-9-tetrahydrocannabinol and 11-nor-9-carboxy- delta-9-tetrahydrocannabinol concentrations. Clin. Chem. 51, 2289-2295 (2005).
34. Perez-Reyes, M., Owens, S.M. & Di Guiseppi, S. The clinical pharmacology and dynamics of marihuana cigarette smoking. J. Clin. Pharmacol. 21, 201-207 (1981).
35. Hotz, M.A., Ritz, R., Linder, L., Scollo-Lavizzari, G. & Haefeli, W.E. Auditory and electroencephalographic effects of midazolam and α-hydroxy-midazolam in healthy subjects. Br. J. Clin. Pharmacol. 49, 72-79 (2000).
36. Skopp, G., Pötsch, L., Mauden, M. & Richter, B. Partition coefficient, blood to plasma ratio, protein binding and short-term stability of 11-nor-delta-9-carboxy tetrahydrocannabinol glucuronide. Forensic Sci. Int. 126, 17-23 (2002).
37. Mauden, M., Skopp, G., Mattern, R. & Aderjan, R. GC/MS-Determination of THCCOOH in serum: Comparison of different processing methods and the influence of THCCOOH-glucuronide. Blutalkohol 37, 48-56 (2000).